Revenue: As of FY2026 Q1, the actual value is USD 301.67 M, beating the estimate of USD 279.06 M.EPS: As of FY2026 Q1, the actual value is USD -0.85, missing the estimate of USD -0.806.EBIT: As of FY2026 Q1, the actual value is USD -131.15 M.<h4>First Quarter 2026 Financial Highlights</h4>Total RevenueGuardant Health, Inc. reported total revenue of $301.7 million for the first quarter of 2026, marking a 48% increase compared to $203.5 million in the same period in 2025.<ul><li>Oncology Revenue: This segment generated $205.0 million, representing a 36% increase, with approximately 86,000 oncology tests performed, a 47% increase from the prior year’s $150.6 million.</li><li>Biopharma &amp; Data Revenue: Revenue from this segment was $53.0 million, an increase of 17% compared to $45.4 million in the prior year period.</li><li>Screening Revenue: This segment saw $41.6 million in revenue, driven by approximately 44,000 Shield screening tests, showing over 600% growth from $5.7 million and 9,000 tests in the prior year period.</li><li>Licensing and Other Revenue: This accounted for $2.1 million, up from $1.9 million in the prior year period.</li></ul>Gross Profit (GAAP)GAAP gross profit was $196.7 million for the first quarter of 2026, a 53% increase from $128.7 million in the prior year period.Gross Margin (GAAP)GAAP gross margin for the first quarter of 2026 was 65%, an increase from 63% in the prior year period.Non-GAAP Gross ProfitNon-GAAP gross profit reached $200.1 million for the first quarter of 2026, a 52% increase from $131.3 million in the prior year period.Non-GAAP Gross MarginNon-GAAP gross margin was 66% for the first quarter of 2026, compared to 65% for the first quarter of 2025.Operating Expenses (GAAP)GAAP operating expenses were $318.1 million for the first quarter of 2026, compared to $239.8 million for the prior year period.<ul><li>Cost of Revenue: This was $104.9 million for the first quarter of 2026, up from $74.7 million in the prior year period.</li><li>Research and Development Expense: This amounted to $91.0 million for the first quarter of 2026, compared to $88.5 million in the prior year period.</li><li>Sales and Marketing Expense: This was $169.1 million for the first quarter of 2026, an increase from $104.3 million in the prior year period.</li><li>General and Administrative Expense: This totaled $57.9 million for the first quarter of 2026, compared to $46.9 million in the prior year period.</li></ul>Non-GAAP Operating ExpensesNon-GAAP operating expenses were $268.1 million for the first quarter of 2026, compared to $199.6 million for the prior year period.Net Loss (GAAP)GAAP net loss was -$112.1 million for the first quarter of 2026, compared to -$95.2 million for the prior year period.Non-GAAP Net LossNon-GAAP net loss was -$58.7 million for the first quarter of 2026, compared to -$61.1 million for the prior year period.Adjusted EBITDA LossAdjusted EBITDA loss was -$58.9 million for the first quarter of 2026, compared to a -$58.5 million loss for the prior year period.<h4>Cash Flow</h4>Free Cash FlowFree cash flow was -$71.2 million for the first quarter of 2026, compared to -$67.1 million for the prior year period.Cash, Cash Equivalents, Restricted Cash and Marketable SecuritiesAs of March 31, 2026, Guardant Health, Inc. held $1.2 billion in cash, cash equivalents, restricted cash, and marketable securities.Net Cash Used in Operating ActivitiesNet cash used in operating activities was -$65.6 million for the first quarter of 2026, compared to -$62.7 million for the prior year period.<h4>2026 Guidance</h4>Guardant Health, Inc. increased its full year 2026 revenue guidance to a range of $1.30 to $1.32 billion, representing 32% to 34% growth. Oncology revenue is now projected to grow 28% to 29%, with volume growth exceeding 35%, while screening revenue is expected to be between $186 million and $198 million, driven by 230,000 to 245,000 Shield tests. The company anticipates non-GAAP gross margin in the range of 64% to 65% and expects free cash flow burn to be $185 million to $195 million, an improvement from $233 million in 2025.

Guardant Health | 8-K: FY2026 Q1 Revenue Beats Estimate at USD 301.67 M